| HOME >> BIOLOGY >> TECHNOLOGY |
BRISBANE, Australia, Feb. 5 /PRNewswire/ -- Xenome Limited today announced the appointment of Ian Nisbet, PhD as the Company's Chief Executive Officer. Dr. Nisbet will also join Xenome's Board as Managing Director.
Dr. Nisbet has previously worked in senior management and executive roles in a number of biotechnology companies, including ChemGenex Pharmaceuticals Ltd, Meditech Research Ltd, Millennium Pharmaceuticals Inc, and CSL Ltd. He is a founder and partner in the biotechnology consultancy company Afandin Pty Ltd. He also serves on the board of the biotechnology companies Verva Pharmaceuticals Ltd, Ambri Ltd and Velacor Pty Ltd.
Xenome Chairman Ian Sandford stated, "We are delighted to have recruited Ian Nisbet to join Xenome. The Company has just executed a major discovery partnership with Amylin Pharmaceuticals and we will soon initiate a Xen2174 phase II study in post-operative pain. With the leadership of such an experienced biotechnology executive as Ian we look forward to the coming year with tremendous excitement and confidence."
"Ian's skills and experience make him the ideal person to lead Xenome in its next stage of development. Ian has worked in a variety of project management, business development, product development and executive management roles. During his time at Millennium he was project leader for the US approval and launch of VELCADE(R) and was part of the team that managed the merger of Millennium and COR Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with Alchemia that resulted in the first merger of two publicly-traded Australian biotechnology companies."
Dr. Nisbet will assume the CEO position immediately and transition from
his existing consultancy commitments over the next several months.
Further information:
Ian Nisbet, Chief Executive Officer
Xenome Ltd.
Tel: +61 431 709 121
E-mail: ian.
'/>"/>
| SOURCE Xenome Ltd. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
2. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
3. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
4. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
7. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
8. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
9. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |